Dermapharm (DMP) has shown strong resilience and growth in 2024, driven by strategic initiatives in the Branded Pharmaceuticals segment, the successful integration of Montavit and a steady recovery in Arkopharma. These factors, combined with improved sourcing strategies, drove revenue and margin expansion, resulting in a reported EBITDA margin of 26.3% in 9M '24. With full-year guidance of EUR 1.17-1.21bn in revenues and EUR 305-315m in adjusted EBITDA in line with mwb research’s assumptions, the company remains on track. Founder Wilhelm Beier has increased his stake to around 75.2%, opening the door to a potential going-private bid. Nevertheless, as the shares have reached the price target of EUR 41.50, the recommendation is changed from BUY to HOLD. The full update can be downloaded under research-hub.de/companies/Dermapharm%20Holding%20SE

LM Pay specializes in providing consumer loans designed to pre-finance medical and dental procedures, including hospital expenses. These loans cover a wide range of medical treatments. Additionally, the company’s business model includes financing veterinary services. LM Pay also sees further growth potential through a partnership with VISA and expansion into neighboring European countries. In this context, mwb research is hosting an online roundtable on January 22, 2025, at 2:00 PM with Jakub Czarzasty, CEO of LM Pay. Following a presentation, attendees will have the opportunity to ask questions. The event is aimed at professional investors and semi-professional private investors and will be conducted online in English. Participation is free of charge, and access details will be provided upon registration at the following link: https://research-hub.de/events/registration/2025-01-22-14-00/Y00-GR?utm_source=brevo&utm_campaign=2025%2002%2001%20Invitation%20to%20LM%20Pay%20Roundtable&utm_medium=email.

Delivery Hero (DH) has encountered a series of challenges after a rather strong performance in 2024. The Taiwan Fair Trade Commission (TFTC) blocked the proposed USD 950 million sale of its foodpanda business to Uber, citing competition concerns. Additionally, DH’s Talabat IPO, while raising EUR 1.9bn, saw a 7.5% first-day share price decline. Regulatory issues with its Glovo subsidiary in Spain further compounded recent headwinds. Despite these setbacks, DH’s operational performance had been solid in the first 9 months, and the company showed promising progress in improving its financial situation. mwb research’s analysts confirm their BUY rating with a price target of EUR 45.00. The full update can be downloaded under https://www.research-hub.de/companies/Delivery%20Hero%20SE

With the completion of its fab sale to Littelfuse, Elmos has begun a new chapter as a fabless powerhouse, unlocking access to top-notch technology from world-class foundry partners like TSMC, enhancing its flexibility, and improving its risk profile. This transformation positions Elmos to thrive in the accelerating autonomous driving revolution, as Waymo leads the charge with tripled yoy paid trips and global expansion, while Tesla and Zoox push the boundaries with bold, innovative concepts. Regulatory backing, such as the NHTSA’s new guidelines, signals readiness for mainstream adoption, fueled by a projected EUR 480bn ride-sharing market by 2032. As vehicle autonomy advances, with L2+ projected to rise from 25% today to over 60% by 2030 and L3-L6 from 0.5% to 7%, Elmos stands out by leveraging its global leadership in Ultrasonic Sensor ICs to capitalize on rising demand, perfectly aligning with its EUR 1bn sales target by 2030. While the industry is experiencing short-term softness, long-term growth catalysts remain intact. mwb research views Elmos as a compelling play for 2025 and beyond, supported by its tactical shift to a fabless powerhouse, attractive valuation, and strategic initiatives paving the way for a record-breaking FCF year in 2025. mwb research’s analysts remain bullish and reiterate their BUY rating with a EUR 105.00 price target. The full update can be downloaded under https://research-hub.de/companies/Elmos%20Semiconductor%20SE

Company Name: European Lithium Limited ISIN: AU000000EUR7   Reason for the research: Update Recommendation: Buy from: 20.12.2024 Target price: €0.14 Target price on sight of: 12 months Last rating change: - Analyst: Simon Scholes First Berlin Equity Research has published a research update on European Lithium Limited (ISIN: [ … ]

Company Name: MPH Health Care AG ISIN: DE000A289V03   Reason for the research: 9M Kennzahlen Recommendation: Kaufen from: 18.12.2024 Target price: €108 Target price on sight of: 12 Monate Last rating change: - Analyst: Ellis Acklin First Berlin Equity Research hat ein Research Update zu MPH Health Care AG (ISIN: DE000A289V0 [ … ]

Company Name: Aspermont Ltd. ISIN: AU000000ASP3   Reason for the research: Research Report (Anno) Recommendation: Buy Target price: 0.03 AUD Target price on sight of: 31.12.2025 Last rating change: Analyst: Julien Desrosiers, Matthias Greiffenberger Strength in Recurring Revenue: The company's core subscription business maintai [ … ]

Company Name: SYNBIOTIC SE ISIN: DE000A3E5A59   Reason for the research: Update Recommendation: BUY from: 18.12.2024 Target price: EUR 12.40 Target price on sight of: 12 months Last rating change: Analyst: Christian Sandherr The new group continues to take shape; chg. est. Topic: While SYNBIOTICs largest holding WEECO performs n [ … ]

Company Name: Advanced Blockchain AG ISIN: DE000A0M93V6   Reason for the research: Management interview Recommendation: Buy Target price: 10.75 EUR Target price on sight of: 31.12.2025 Last rating change: Analyst: Matthias Greiffenberger, Marcel Goldmann GBC AG: What key topics and projects did you present at the Eigenkapitalfo [ … ]

Company Name: M1 Kliniken AG ISIN: DE000A0STSQ8   Reason for the research: 9M Hauptkennzahlen Recommendation: Kaufen from: 17.12.2024 Target price: €28 Target price on sight of: 12 Monate Last rating change: - Analyst: Ellis Acklin First Berlin Equity Research hat ein Research Update zu M1 Kliniken AG (ISIN: DE000A0STSQ8) v [ … ]